The effect of peripheral neuropathy induced the Oxaliplatin in patients with colon cancer

• Aisha Ashammam

  Higher Institute of Science and Medical Technology, Pharmacy Department, Tripoli/Abusalim

  Author

• Amal Masri Iwhida

  Higher Institute of Science and Medical Technology, Pharmacy Department, Tripoli/Abusalim

  Author

• Dr. Omaro A. Aburas

  Higher Institute of Science and Medical Technology, Pharmacy Department, Tripoli/Abusalim

  Author

• Abtisam Miftah Dhaw

  Higher Institute of Science and Medical Technology, Pharmacy Department, Tripoli/Abusalim

  Author

• Emhamed Boras

  Libyan Academy of postgraduate Studies, Life Science Department, Tripoli/ Janzor

  Author

Colon cancer is one the most common forms of cancer in both sexes. Due to important progress in the field of early detection and effective treatment, colon and rectal cancer survivors currently account for 10% of cancer survivors worldwide. However, the effects of anti-cancer treatments, especially oxaliplatin-based chemotherapy, on the quality of life (QoL) have been less evaluated. Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrain cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. Objective of the study: determining the effect of acute toxicity neuropathy caused by oxaliplatin and its effect on the lives of selected patients. Patients and methods A hospital-based observation study was conducted during a 4-month period on 50 patients with colon cancer who were interviewed and reviewed in the oncology department at Tripoli University Hospital. Results: A total of 50 patients participated in the study; the majority were male (70%) and were more than 50 years old (76.0%). Over three-quarters (76.0%) of the patients work in an enclosed space. We found that the majority (86.0%) of patients were non-smokers, that two-thirds (66.0%) of patients were at stage 3 of the disease, nearly a quarter (26.0%) at stage 4, only four patients (8.0%) at stage 2, and no patient at stage 0 or stage 1. reported that (32.0%) of patients receiving oxaliplatin had kinetic symptoms, (48.0%) had sensory symptoms, and 20% had movement symptoms. As for neurotoxicity, 10 cases had chest pain only (20%), and 6 cases had difficulty breathing only (12%) and when we counted the cases that combined both symptoms, 3 cases showed symptoms of acute toxicity all at the same time. Conclusion: We concluded that males over the age of 50 are more likely to develop colon cancer and that neuropathy is not related to its effect by increasing the cumulative dose, but is related to the number of doses taken by the patient and the disease, and by neurotoxicity was 10 cases suffered from chest pain and 6 from difficulty breathing and 3 cases appeared on them  symptomatic together, and in proportion to the symptoms of general neuropathy has appeared on all 50 cases that we conducted purely on them has suffered 16 cases out of 50 of the symptoms of subjective symptoms only 32%, and sensory symptoms appeared by 24 cases out of 50 cases by 48%, and motor symptoms on 10 cases out of 50 by 20%, the most targeted patients with oxaliplatin are patients of the third stage 66% were fourth 26% who suffer from chronic diseases such as sugar and blood pressure

• pdf

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.